Evidence map›Paper›PMID 35160232›Full record

ArticleJournal of clinical medicine2022

Resistance to Antimalarial Monotherapy Is Cyclic.

Rachel Weitzman, Ortal Calfon-Peretz, Trishna Saha, Naamah Bloch, Karin Ben Zaken, Avi Rosenfeld, Moshe Amitay, Abraham O Samson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rachel WeitzmanBioinformatic Department, Jerusalem College of Technology, Jerusalem 9372115, Israel.
Ortal Calfon-PeretzBioinformatic Department, Jerusalem College of Technology, Jerusalem 9372115, Israel.ORCID 0000-0001-6563-5216
Trishna SahaDrug Discovery Lab, Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.ORCID 0000-0002-6951-956X
Naamah BlochDrug Discovery Lab, Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Karin Ben ZakenDrug Discovery Lab, Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Avi RosenfeldDepartment of Computer Science, Jerusalem College of Technology, Jerusalem 9372115, Israel.
Moshe AmitayBioinformatic Department, Jerusalem College of Technology, Jerusalem 9372115, Israel.ORCID 0000-0002-6897-9580
Abraham O SamsonDrug Discovery Lab, Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.ORCID 0000-0001-7436-3515
Bar-Ilan University · ILJerusalem College of Technology · IL

Funding

Ginsberg Foundation NAKatz foundation NA
6 · The paper itself

Abstract

Malaria is a prevalent parasitic disease that is estimated to kill between one and two million people-mostly children-every year. Here, we query PubMed for malaria drug resistance and plot the yearly citations of 14 common antimalarials. Remarkably, most antimalarial drugs display cyclic resistance patterns, rising and falling over four decades. The antimalarial drugs that exhibit cyclic resistance are quinine, chloroquine, mefloquine, amodiaquine, artesunate, artemether, sulfadoxine, doxycycline, halofantrine, piperaquine, pyrimethamine, atovaquone, artemisinin, and dihydroartemisinin. Exceptionally, the resistance of the two latter drugs can also correlate with a linear rise. Our predicted antimalarial drug resistance is consistent with clinical data reported by the Worldwide Antimalarial Resistance Network (WWARN) and validates our methodology. Notably, the cyclical resistance suggests that most antimalarial drugs are sustainable in the end. Furthermore, cyclic resistance is clinically relevant and discourages routine monotherapy, in particular, while resistance is on the rise. Finally, cyclic resistance encourages the combination of antimalarial drugs at distinct phases of resistance.

Indexed as

antibiotic resistanceantimalarial resistancedrug of choicedrug resistancehealth policymalariaparasitologyPlasmodiumPlasmodium falciparumPlasmodium vivaxtext-mining

Identifiers

PMID35160232
PMCPMC8836566
OpenAlexW4210462905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.